A Pilot Phase II Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral AND017 to Treat Anemia in Nondialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
Latest Information Update: 06 Oct 2023
At a glance
- Drugs AND-017 (Primary)
- Indications Anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kind Pharmaceuticals
- 02 Oct 2023 Status changed from active, no longer recruiting to completed.
- 10 Apr 2023 Planned primary completion date changed from 1 Aug 2023 to 1 May 2023.
- 10 Apr 2023 Status changed from recruiting to active, no longer recruiting.